FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Essetifin SPA 2. Issuer Name and Ticker or Trading Symbol REGENERX BIOPHARMACEUTICALS INC [ RGRX ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    __X__ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)         (First)         (Middle)
VIA SUDAFRICA, 20
3. Date of Earliest Transaction (MM/DD/YYYY)
10/15/2020
(Street)
ROME, L6 00144
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) ___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock                 34989080  D (7)  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Convertible Promissory Note (right to buy)  $0.12 (1)(2)                 2/26/2019   (1)(2) Common Stock   (1)(2)   $500000 (1)(2) D (7)  
Common Stock Warrant (right to buy)  $0.18 (1)(3)                 8/26/2019  2/26/2024  Common Stock  3125000 (1)(3)   3125000 (1)(3) D (7)  
Convertible Promissory Note (right to buy)  $0.12 (1)(2)                 5/13/2019   (1)(2) Common Stock   (1)(2)   $500000 (1)(2) D (7)  
Common Stock Warrant (right to buy)  $0.18 (1)(3)                 11/13/2019  3/1/2024  Common Stock  3125000 (1)(3)   3125000 (1)(3) D (7)  
Convertible Promissory Note (right to buy)   (4)(5) 10/15/2020    P     $400000 (4)(5)     10/15/2020   (4)(5) Common Stock   (4)(5) $400000 (4)(5) $400000 (4)(5) D (7)  
Common Stock Warrant (right to buy)  $0.45 (4)(6) 10/15/2020    J     835189 (4)(6)     4/15/2021  10/15/2025  Common Stock  835189 (4)(6)  (4)(6) 835189 (4)(6) D (7)  

Explanation of Responses:
(1)  On February 26, 2019, in a private placement by the issuer, Essetifin S.p.A. ("Essetifin") entered into a Convertible Note and Warrant Purchase Agreement (the "2019 Agreement"), pursuant to which it agreed to purchase an aggregate principal amount of $1,000,000 of convertible promissory notes of the issuer (the "2019 Notes") and warrants to acquire the issuer's common stock (the "2019 Warrants"), in two $500,000 tranches. Each tranche consisted of (i) a note in the principal amount of $500,000 and (ii) a warrant to purchase 3,125,000 shares of the issuer's common stock at an exercise price of $0.18 per share, issued in connection with the 2019 Agreement as partial consideration for the note. Essetifin purchased the first $500,000 tranche effective February 26, 2019 (such purchase consisting of the "February 2019 Note" and the "February 2019 Warrant") and the second $500,000 tranche effective May 13, 2019 (such purchase consisting of the "May 2019 Note" and the "May 2019 Warrant").
(2)  The 2019 Notes and any accrued interest thereon are convertible at the option of the holder at any time prior to repayment of the 2019 Notes into shares of the issuer's common stock at a conversion price of $0.12 per share. The 2019 Notes are payable upon the written demand of the holder thereof at any time after March 1, 2024. Interest accrues on the unpaid principal amount at a rate equal to 5% per annum, but it is not due and payable until the written demand of the holder for payment on or after the maturity date. The current outstanding principal amount, if converted into common stock, would result in the issuance of 8,333,334 shares, or 4,166,667 shares upon the conversion of each of the February 2019 Note and May 2019 Note. The number of shares of common stock to be issued upon conversion will be fixed on the conversion date and reported on a Form 4 within two business days after conversion.
(3)  Each of the February 2019 Warrant and the May 2019 Warrant is exercisable into up to 3,125,000 shares of the issuer's common stock, or an aggregate of 6,250,000 shares. The February 2019 Warrant is exercisable, in whole or in part, at any time and from time to time, from August 26, 2019, the date that is six months after the date of purchase, through February 26, 2024, the fifth anniversary of such date. The May 2019 Warrant is exercisable, in whole or in part, at any time and from time to time, from November 13, 2019, the date that is six months after the date of purchase, through March 1, 2024, at which time it is void.
(4)  On October 15, 2020, in a private placement by the issuer, Essetifin entered into a Convertible Note and Warrant Purchase Agreement (the "2020 Agreement"), pursuant to which it agreed to purchase, for an aggregate purchase price of $400,000, (i) a convertible promissory note in the principal amount of $400,000 (the "2020 Note") and (ii) a warrant to purchase 835,189 shares of common stock at an exercise price of $0.45 per share, issued in connection with the 2020 Agreement as partial consideration for the 2020 Note (the "2020 Warrant").
(5)  The 2020 Note and any accrued interest thereon are convertible at the option of the holder at any time prior to repayment of the 2020 Note into shares of the issuer's common stock at a conversion price equal to the closing price of the issuer's common stock as of October 14, 2020, less a 20% discount (approximately $0.3592 per share). The 2020 Note is payable upon the written demand of the holder thereof at any time after October 14, 2025. Interest accrues on the unpaid principal amount at a rate equal to 5% per annum, but it is not due and payable until the written demand of the holder for payment on or after the maturity date. The current outstanding principal amount, if converted into common stock, would result in the issuance of 1,113,586 shares. The number of shares of common stock to be issued upon conversion will be fixed on the conversion date and reported on a Form 4 within two business days after conversion.
(6)  The 2020 Warrant is exercisable into up to 835,189 shares of the issuer's common stock and is exercisable, in whole or in part, at any time and from time to time, from April 15, 2021, the date that is six months after the date of purchase, through October 15, 2025, the fifth anniversary of such date.
(7)  Dispositive power over the shares of the issuer's common stock owned by Essetifin is shared by Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza. Each of Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza disclaims beneficial ownership of all shares of Common Stock held by Essetifin except to the extent of any pecuniary interest therein.

Remarks:
Exhibit List: Exhibit 99.1 - Joint Filers' Signatures

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Essetifin SPA
VIA SUDAFRICA, 20
ROME, L6 00144

X

CAVAZZA PAOLO
VIA TESSERETE, 10
LUGANO, V8 00000

X

Cavazza Enrico
VIA SUDAFRICA, 20
ROME, L6 00144

X

Cavazza Francesca
VIA SUDAFRICA, 20
ROME, L6 00144

X

Cavazza Silvia
VIA SUDAFRICA, 20
ROME, L6 00144

X

Cavazza Preta Martina
VIA SUDAFRICA, 20
ROME, L6 00144

X


Signatures
Essetifin S.p.A. By: /s/ Marino Zigrossi 10/16/2020
**Signature of Reporting Person Date
/s/ Marino Zigrossi for Enrico Cavazza by power of attorney 10/16/2020
**Signature of Reporting Person Date
/s/ Marino Zigrossi for Francesca Cavazza by power of attorney 10/16/2020
**Signature of Reporting Person Date
/s/ Marino Zigrossi for Silvia Cavazza by power of attorney 10/16/2020
**Signature of Reporting Person Date
/s/ Marino Zigrossi for Martina Cavazza Preta by power of attorney 10/16/2020
**Signature of Reporting Person Date
/s/ Fabio Poma for Paolo Cavazza by power of attorney 10/16/2020
**Signature of Reporting Person Date
RegeneRX Biopharmaceutic... (QB) (USOTC:RGRX)
Historical Stock Chart
From Nov 2020 to Dec 2020 Click Here for more RegeneRX Biopharmaceutic... (QB) Charts.
RegeneRX Biopharmaceutic... (QB) (USOTC:RGRX)
Historical Stock Chart
From Dec 2019 to Dec 2020 Click Here for more RegeneRX Biopharmaceutic... (QB) Charts.